How effective is entrectinib?

Entrectinibis a tropomyosin receptor tyrosine kinaseTRKA/B/C, proto-oncogene tyrosine protein kinaseROS Orally active, CNS-penetrating small molecule selective inhibitor of 1 and the anaplastic lymphoma kinase gene (ALK). Entrectinibapproved for treatment of age≥ Adult and pediatric patients aged 12NTRKfusion-positive (NTRK+) solid tumors and adult patients with ROS1fusion-positive (ROS1+) non-small cell lung cancer.

Objective response rate67%(95%Confidence interval:59.3–74.3), the median duration of response (DoR) was 15.7 months (95% CI: 13.9–28.6), and the median progression-free survival (PFS) was 15.7 months (95% CI: 11.0–21.1). The effect is still optimistic.

Entrectinib belongs to the kinase inhibitor class of drugs. Entrectinib works by blocking the activity of abnormal proteins, which are signals for cancer cell reproduction. This helps prevent or slow down the spread of cancer cells. EnrectinibThe most common adverse reactions (≥ 20%) are fatigue, constipation, dysgeusia, edema, dizziness, diarrhea, nausea, dysesthesia, dyspnea, myalgia, cognitive impairment, weight gain, cough, vomiting, fever, joint pain, and visual impairment. There are generic drugs in Laos, the officially marketed version, with government approval, retail price of pharmaceuticals in Laos and ASEAN200mg90tablets20000yuan, 100mg30 tablets6500yuan. If you want to get more quality information, please contactYaoDe,YaoDe will do its best to learn more about overseas high-quality drugs for you.

xa0

xa0